Publications

2018

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.

Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, Butler R, Shafren D, Au G, Knowles M, Harrington K, Vile R, Melcher A, Pandha H. Mol Ther Oncolytics. 2018 Feb 14;9:1-12

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, et al. Nat Commun. 2018 Jun 11;9(1):2256

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, et al. Nat Genet. 2018 Jun 11.

AA9int: SNP Interaction Pattern Search Using Non-Hierarchical Additive Model Set.

Lin HY, Huang PY, Chen DT et al.

Bioinformatics. 2018 Jun 7.

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

Patel PM, Ottensmeier CH, Mulatero C et al.

Oncoimmunology. 2018 Feb 22;7(6):e1433516.

Synergistic antitumour effects of rapamycin and oncolytic reovirus.

Comins C, Simpson GR, Rogers W, Relph K, Harrington K, Melcher A, Roulstone V, Kyula J, Pandha H.

Cancer Gene Ther. 2018 May 3. doi: 10.1038/s41417-018-0011-8.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Grönberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2018 Mar 20;118(6):e9. doi: 10.1038/bjc.2017.468

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators.

N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Apr 1;24(7):1554-1561. doi: 10.1158/1078-0432.CCR-17-2822.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Khan AA, Paget JT, McLaughlin M, Kyula JN, Wilkinson MJ, Pencavel T, Mansfield D, Roulstone V, Seth R, Halle M, Somaiah N, Boult JKR, Robinson SP, Pandha HS, Vile RG, Melcher AA, Harris PA, Harrington KJ.

Sci Transl Med. 2018 Jan 24;10(425).

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TL, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Cuk K, Saum KU, Park JY, Sellers TA, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Karow DS, Mills IG, Andreassen OA, Dale AM; PRACTICAL Consortium*.

BMJ. 2018 Jan 10;360:j5757.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577.

 

2017

Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells.

Alharbi RA, Pandha HS, Simpson GR, Pettengell R, Poterlowicz K, Thompson A, Harrington K, El-Tanani M, Morgan R.

Oncotarget. 2017 Aug 7;8(52):89566-89579.

 

Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study.

Dimitrakopoulou VI, Tsilidis KK, Haycock PC, Dimou NL, Al-Dabhani K, Martin RM, Lewis SJ, Gunter MJ, Mondul A, Shui IM, Theodoratou E, Nimptsch K, Lindström S, Albanes D, Kühn T, Key TJ, Travis RC, Vimaleswaran KS; GECCO Consortium; PRACTICAL Consortium; GAME-ON Network (CORECT, DRIVE, ELLIPSE, FOCI-OCAC, TRICL-ILCCO), Kraft P, Pierce BL, Schildkraut JM.

BMJ. 2017 Oct 31;359:j4761

.

Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.

Kottke T, Evgin L, Shim KG, Rommelfanger D, Boisgerault N, Zaidi S, Diaz RM, Thompson J, Ilett E, Coffey M, Selby P, Pandha H, Harrington K, Melcher A, Vile R.

Cancer Immunol Res. 2017 Nov;5(11):1029-1045

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68.

Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, Garcia SB, Neal DE, Hamdy FC, Donovan JL, Giles GG, Fitzgerald LM, Southey MC, Pharoah P, Pashayan N, Gronberg H, Wiklund F, Aly M, Stanford JL, Brenner H, Dieffenbach AK, Arndt V, Park JY, Lin HY, Sellers T, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA; APCB BioResource; PRACTICAL consortium, Easton D, Eeles RA, Muir K.

Br J Cancer. 2017 Aug 22;117(5):734-743.

Targeting HOX/PBX dimers in cancer.

Morgan R, El-Tanani M, Hunter KD, Harrington KJ, Pandha HS.

Oncotarget. 2017 May 9;8(19):32322-32331

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD.

Eur Urol. 2017 Oct;72(4):509-518.

Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.

Zuber V, Bettella F, Witoelar A; PRACTICAL Consortium; CRUK GWAS; BCAC Consortium; TRICL Consortium, Andreassen OA, Mills IG, Urbanucci A.

BMC Genomics. 2017 Mar 31;18(1):270

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma.

Iyer R, Montgomery B, Pandha HS.

Indian J Urol. 2017 Jan-Mar;33(1):76-78.

SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns.

Lin HY, Chen DT, Huang PY, Liu YH, Ochoa A, Zabaleta J, Mercante DE, Fang Z, Sellers TA, Pow-Sang JM, Cheng CH, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Hamdy F, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Batra J, Teixeira MR, Pandha H, Lu YJ; PRACTICAL Consortium, Park JY.

Bioinformatics. 2017 Mar 15;33(6):822-833

Validation of a protein panel for the noninvasive detection of recurrent non-muscle invasive bladder cancer.

Gogalic S, Sauer U, Doppler S, Heinzel A, Perco P, Lukas A, Simpson G, Pandha H, Horvath A, Preininger C.

Biomarkers. 2017 Nov;22(7):674-681

Immunogenicity of self tumor associated proteins is enhanced through protein truncation.

Kottke T, Shim KG, Alonso-Camino V, Zaidi S, Maria Diaz R, Pulido J, Thompson J, Rajani KR, Evgin L, Ilett E, Pandha H, Harrington K, Selby P, Melcher A, Vile R.

Mol Ther Oncolytics. 2016 Dec 7;3:16030. eCollection 2016.

Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis.

Taylor AE, Martin RM, Geybels MS, Stanford JL, Shui I, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Blot W, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; PRACTICAL Consortium, Donovan J, Munafò MR.

Int J Cancer. 2017 Jan 15;140(2):322-328.

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.

Ilett E, Kottke T, Thompson J, Rajani K, Zaidi S, Evgin L, Coffey M, Ralph C, Diaz R, Pandha H, Harrington K, Selby P, Bram R, Melcher A, Vile R.

Gene Ther. 2017 Jan;24(1):21-30.

 

2016

Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.

Larkin SE, Johnston HE, Jackson TR, Jamieson DG, Roumeliotis TI, Mockridge CI, Michael A, Manousopoulou A, Papachristou EK, Brown MD, Clarke NW, Pandha H, Aukim-Hastie CL, Cragg MS, Garbis SD, Townsend PA.

Br J Cancer. 2016 Oct 25;115(9):1078-1086.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators.

N Engl J Med. 2016 Dec 8;375(23):2246-2254.

Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis.

De Paoli M, Gogalic S, Sauer U, Preininger C, Pandha H, Simpson G, Horvath A, Marquette C.

Dis Markers. 2016;2016:4591910.

Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study.

Brunner C, Davies NM, Martin RM, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles G, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Donovan J, Hamdy FC, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; PRACTICAL Consortium,, Zuccolo L.

Int J Cancer. 2017 Jan 1;140(1):75-85

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances.

Simpson GR, Relph K, Harrington K, Melcher A, Pandha H.

Oncolytic Virother. 2016 Jan 6;5:1-13.

Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium.

Khankari NK, Murff HJ, Zeng C, Wen W, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Donovan JL, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H, Zheng W; PRACTICAL consortium.

Br J Cancer. 2016 Aug 23;115(5):624-31.

Science in Focus - Oncolytic Viruses: New Multifunctional Immunotherapeutics.

Pandha HS.

Clin Oncol (R Coll Radiol). 2016 Oct;28(10):615-8.

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ; ABCTB Investigators, Kibel AS, Dansonka-Mieszkowska A, et al.

Cancer Discov. 2016 Sep;6(9):1052-67.

Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels.

Bonilla C, Lewis SJ, Rowlands MA, Gaunt TR, Davey Smith G, Gunnell D, Palmer T, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Grönberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; PRACTICAL consortium, Lathrop M, Martin RM, Holly JM.

Int J Cancer. 2016 Oct 1;139(7):1520-33

The prognostic significance of specific HOX gene expression patterns in ovarian cancer.

Kelly Z, Moller-Levet C, McGrath S, Butler-Manuel S, Kavitha Madhuri T, Kierzek AM, Pandha H, Morgan R, Michael A.

Int J Cancer. 2016 Oct 1;139(7):1608-17.

Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.

Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, et al.

Nat Commun. 2016 Apr 7;7:10979.

Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort.

Bonilla C, Lewis SJ, Martin RM, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H, Lathrop M, Davey Smith G; PRACTICAL consortium.

BMC Med. 2016 Apr 4;14:66.

Blood lipids and prostate cancer: a Mendelian randomization analysis.

Bull CJ, Bonilla C, Holly JM, Perks CM, Davies N, Haycock P, Yu OH, Richards JB, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, MacInnis RJ, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Micheal A, Pandha H, Smith GD, Lewis SJ, Martin RM; PRACTICAL consortium.

Cancer Med. 2016 Jun;5(6):1125-36.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52.

First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.

Takyar S, Diaz J, Sehgal M, Sapunar F, Pandha H.

Anticancer Drugs. 2016 Jun;27(5):383-97

HOX transcription factors are potential targets and markers in malignant mesothelioma.

Morgan R, Simpson G, Gray S, Gillett C, Tabi Z, Spicer J, Harrington KJ, Pandha HS.

BMC Cancer. 2016 Feb 11;16:85.

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roulstone V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoo V, Harrington KJ.

Gene Ther. 2016 Apr;23(4):357-68.

Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression.

Crea F, Quagliata L, Michael A, Liu HH, Frumento P, Azad AA, Xue H, Pikor L, Watahiki A, Morant R, Eppenberger-Castori S, Wang Y, Parolia A, Lennox KA, Lam WL, Gleave M, Chi KN, Pandha H, Wang Y, Helgason CD.

Mol Oncol. 2016 May;10(5):693-703.

 

2015

Talimogene laherparepvec in the treatment of melanoma.

Appleton ES, Turnbull S, Ralph C, West E, Scott K, Harrington K, Pandha H, Melcher A.

Expert Opin Biol Ther. 2015;15(10):1517-30. Review.

Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.

Blanchard M, Shim KG, Grams MP, Rajani K, Diaz RM, Furutani KM, Thompson J, Olivier KR, Park SS, Markovic SN, Pandha H, Melcher A, Harrington K, Zaidi S, Vile R.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):577-87.

EN2 in Prostate Cancer.

McGrath SE, Michael A, Morgan R, Pandha H.

Adv Clin Chem. 2015;71:47-76.

The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium.

Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, Kemp JP, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; PRACTICAL consortium, Lathrop M, Smith GD, Martin RM.

Cancer Causes Control. 2015 Nov;26(11):1603-16.

Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic.

De Paoli M, Perco P, Mühlberger I, Lukas A, Pandha H, Morgan R, Feng GJ, Marquette C.

Biomarkers. 2015;20(5):328-37.

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz RM, Pandha H, Harrington K, Coffey M, Melcher A, Vile R.

Mol Ther. 2016 Feb;24(1):166-74.

Genome-wide association study of prostate cancer-specific survival.

Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG,et al.

Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1796-800.

Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015.

Pandha H, Pawelec G.

Cancer Immunol Immunother. 2015 Sep;64(9):1071-4.

Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic.

De Paoli M, Perco P, Mühlberger I, Lukas A, Pandha H, Morgan R, Feng GJ, Marquette C.

Biomarkers. 2015 Jul 31:1-10.

Prediction of individual genetic risk to prostate cancer using a polygenic score.

Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, Kote-Jarai ZS, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubiński J, Kluźniak W, Cannon-Albright L, Brenner H, Butterbach K, Stegmaier C, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA; Australian Prostate Cancer BioResource, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A; Practical Consortium, Gronberg H, Wiklund F.

Prostate. 2015 Sep;75(13):1467-74.

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, et al.

Hum Mol Genet. 2015 Oct 1;24(19):5589-602.

The tolerability of sunitinib in elderly patients with metastatic renal cancer.

Michael A, Coward J, Brown A, Barber N, Pandha H.

Clin Oncol (R Coll Radiol). 2015 Jun;27(6):371-2.

Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma.

Seth R, Khan AA, Pencavel TD, Wilkinson MJ, Kyula JN, Simpson G, Pandha H, Melcher A, Vile R, Harris PA, Harrington KJ.

Plast Reconstr Surg. 2015 Feb;135(2):475-87.

BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.

Roulstone V, Pedersen M, Kyula J, Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E, Coffey M, Marais R, Jebar A, Errington-Mais F, Melcher A, Vile R, Pandha H, McLaughlin M, Harrington KJ.

Mol Ther. 2015 May;23(5):931-942.

Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.

Zaidi S, Blanchard M, Shim K, Ilett E, Rajani K, Parrish C, Boisgerault N, Kottke T, Thompson J, Celis E, Pulido J, Selby P, Pandha H, Melcher A, Harrington K, Vile R.

Mol Ther. 2015 May;23(5):845-856.

Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.

Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA, Vile R, Harrington KJ, de Bono J, Spicer J.

Clin Cancer Res. 2015 Mar 15;21(6):1305-12.

 

2014

Highlights from the field of biomarkers in prostate cancer. [corrected].

Pandha H.

Biomark Med. 2014;8(7):917-9.

A genome-wide pleiotropy scan for prostate cancer risk.

Panagiotou OA, Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, Schumacher FR, Siddiq A, Papatheodorou SI, Stanford JL, Albanes D, Virtamo J, Weinstein SJ, Diver WR, Gapstur SM, Stevens VL, Boeing H, Bueno-de-Mesquita HB, Barricarte Gurrea A, Kaaks R, Khaw KT, Krogh V, Overvad K, Riboli E, Trichopoulos D, Giovannucci E, Stampfer M, Haiman C, Henderson B, Le Marchand L, Gaziano JM, Hunter DJ, Koutros S, Yeager M, Hoover RN; PRACTICAL Consortium, Chanock SJ, Wacholder S, Key TJ, Tsilidis KK.

Eur Urol. 2015 Apr;67(4):649-57.

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.

Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Røder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokołorczyk D, Kluźniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; COGS (Collaborative Oncological Gene-environment Study) Consortium; GAME-ON/ELLIPSE Consortium, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA.

Nat Genet. 2014 Oct;46(10):1103-9.

The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.

Alonso-Camino V, Rajani K, Kottke T, Rommelfanger-Konkol D, Zaidi S, Thompson J, Pulido J, Ilett E, Donnelly O, Selby P, Pandha H, Melcher A, Harrington K, Diaz RM, Vile R.

Mol Ther. 2014 Nov;22(11):1936-48.

Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.

Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, Zaidi S, Coffey M, Selby P, Harrington K, Pandha H, Melcher A, Vile R.

Mol Ther. 2014 Oct;22(10):1851-63.

Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.

Annels NE, Simpson GR, Denyer M, McGrath SE, Falgari G, Killick E, Eeles R, Stebbing J, Pchejetski D, Cutress R, Murray N, Michael A, Pandha H.

Clin Exp Immunol. 2014 Aug;177(2):428-38.

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.

de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN.

Clin Cancer Res. 2014 Apr 1;20(7):1925-34

Targeting HOX transcription factors in prostate cancer.

Morgan R, Boxall A, Harrington KJ, Simpson GR, Michael A, Pandha HS.

BMC Urol. 2014 Feb 5;14:17.

Applications of coxsackievirus A21 in oncology.

Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F.

Oncolytic Virother. 2014 Apr 10;3:47-55.

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D, Pandha H, Neoptolemos JP, Middleton G.

Cancer Immunol Immunother. 2014 Feb;63(2):175-83.

 

2013

Donnelly O, Harrington K, Melcher A, Pandha H Live viruses to treat cancer. J R Soc Med. 2013 Aug;106(8):310-4.

 

Killick E, Morgan R, Launchbury F, Bancroft E, Page E, Castro E, Kote-Jarai Z, Aprikian A, Blanco I, Clowes V, Domchek S, Douglas F, Eccles D, Evans DG, Harris M, Kirk J, Lam J, Lindeman G, Mitchell G, Pachter N, Selkirk C, Tucker K, Zgajnar J, Eeles R, Pandha H. Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci Rep. 2013;3:2059.

 

Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile R. Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse. Mol Ther. 2013 Aug;21(8):1507-16

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling. Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ. Oncogene. 2013 Apr 29.

Prostate cancer vaccines. Michael A, Relph K, Annels N, Pandha H. . Expert Rev Vaccines. 2013 Mar;12(3):253-62.

Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker.

Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, James ND, Wallace DM, Hurst CD, Ward DG, Knowles MA, Pandha H.

Eur J Cancer. 2013 Feb 21. doi:pii: S0959-8049(13)00081-6. 10.1016/j.ejca.2013.01.019. [Epub ahead of print]

 

The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway.

Errico MC, Felicetti F, Bottero L, Mattia G, Boe A, Felli N, Petrini M, Bellenghi M, Pandha HS, Calvaruso M, Tripodo C, Colombo MP, Morgan R, Carè A.

Int J Cancer. 2013 Feb 7. doi: 10.1002/ijc.28097. [Epub ahead of print]

 

Engrailed homeobox transcription factors as potential markers and targets in cancer.

McGrath SE, Michael A, Pandha H, Morgan R.

FEBS Lett. 2013 Feb 7. doi:pii: S0014-5793(13)00099-9. 10.1016/j.febslet.2013.01.054. [Epub ahead of print]

 

Senescence evasion in melanoma progression: uncoupling of DNA-damage signaling from p53 activation and p21 expression.

Mackenzie Ross AD, Cook MG, Chong H, Hossain M, Pandha HS, Bennett DC.

Pigment Cell Melanoma Res. 2013 Mar;26(2):226-35. doi: 10.1111/pcmr.12060. Epub 2013 Jan 14.

 

The role of HOX genes in normal hematopoiesis and acute leukemia.

Alharbi RA, Pettengell R, Pandha HS, Morgan R.

Leukemia. 2012 Dec 5. doi: 10.1038/leu.2012.356. [Epub ahead of print]

 

Basaloid carcinoma of the prostate: A literature review with case report.

Tuan J, Pandha H, Corbishley C, Khoo V.

Indian J Urol. 2012 Jul;28(3):322-4. doi: 10.4103/0970-1591.102714.

 

Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.

Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA.

Int J Cancer. 2013 May 15;132(10):2327-38. doi: 10.1002/ijc.27918. Epub 2012 Nov 26.

 

Targeting the HOX/PBX dimer in breast cancer.

Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS.

Breast Cancer Res Treat. 2012 Nov;136(2):389-98. doi: 10.1007/s10549-012-2259-2. Epub 2012 Sep 30.

 

The hitchhiker's guide to virotherapy.

Donnelly O, Vile R, Pandha H, Harrington K, Melcher A.

Oncotarget. 2012 Aug;3(8):735-6. No abstract available.

 

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.

Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

Oral Oncol. 2013 Feb;49(2):108-18. doi: 10.1016/j.oraloncology.2012.07.019. Epub 2012 Aug 25.

 

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

BMC Cancer. 2012 Aug 24;12:368. doi: 10.1186/1471-2407-12-368.

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ.

Gene Ther. 2012 Aug 16. doi: 10.1038/gt.2012.68. [Epub ahead of print]

 

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, Beirne D, West EJ, Jennings VA, Rose A, Kyula J, Fraser S, Dave R, Anthoney DA, Merrick A, Prestwich R, Aldouri A, Donnelly O, Pandha H, Coffey M, Selby P, Vile R, Toogood G, Harrington K, Melcher AA.

Sci Transl Med. 2012 Jun 13;4(138):138ra77. doi: 10.1126/scitranslmed.3003578.

 

Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.

Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, Morgan R.

BJU Int. 2012 Sep;110(6 Pt B):E287-92. doi: 10.1111/j.1464-410X.2012.11208.x. Epub 2012 May 15.

 

Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.

Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R.

Nat Biotechnol. 2012 Mar 18;30(4):337-43. doi: 10.1038/nbt.2157.

 

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ.

Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7.

 

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.

Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS.

Br J Cancer. 2012 Jan 31;106(3):496-507. doi: 10.1038/bjc.2011.577. Epub 2012 Jan 12.

 

Measles virus causes immunogenic cell death in human melanoma.

Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA.

Gene Ther. 2013 Jan;20(1):7-15. doi: 10.1038/gt.2011.205. Epub 2011 Dec 15.

 

Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?

Middleton GW, Annels NE, Pandha HS.

Cancer Immunol Immunother. 2012 Jan;61(1):1-7. doi: 10.1007/s00262-011-1151-y. Epub 2011 Nov 16. Review.

 

Antiangiogenic effects of zoledronate on cancer neovasculature.

Metcalf S, Pandha HS, Morgan R.

Future Oncol. 2011 Nov;7(11):1325-33. doi: 10.2217/fon.11.113. Review

 

 

 

2011

 

 

Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med. 2011 Jun 19.

Heinemann L, Simpson GR, Boxall A, Kottke T, Relph K, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer. 2011 Jun 6;11(1):221.

 

Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011 Jun 5.

4. Hamdan S, Verbeke CS, Fox N, Booth J, Bottley G, Pandha HS, Blair GE The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells. Cancer Gene Ther. 2011 May 13.

 

Gray S, Pandha HS, Michael A, Middleton G, Morgan R. HOX Genes in Pancreatic Development and Cancer. Journal of the pancreas. 2011 May 6;12(3):216-9.

 

Ilett EJ, Barcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, et al. Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from Neutralization. Clin Cancer Res. 2011 Mar 9 6.747

 

Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, et al. Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2011 Mar 1;17(5):1090-8. 6.747

 

Steele L, Errington F, Prestwich R, Ilett E, Harrington K, Pandha H, et al. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer. 2011;10:20. 4.160

 

Baynes S WB, Ismail M, Khadra A, Davies J, . Cryochock following laparoscopic-assisted renal cryotherapy for renal cell carcinoma: a case report and review of literatures. Current Urology. 2011;5.

 

Ismail M SA, Davies aJ. Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. British Journal Urology International. 2011;107:1009-10. 2.865

 

2010

 

Anesti AM, Simpson GR, Price T, Pandha HS, Coffin RS. Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo. BMC Cancer. 2010;10:486. 2.736

 

Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res. 2010 Nov 15;16(22):5564-72. 6.747

 

Daniels TR, Neacato, II, Rodriguez JA, Pandha HS, Morgan R, Penichet ML. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia. 2010 Sep;24(9):1555-65. 8.296

 

Dash P, Barnett PV, Denyer MS, Jackson T, Stirling CM, Hawes PC, et al. Foot-and-mouth disease virus replicates only transiently in well-differentiated porcine nasal epithelial cells. J Virol. 2010 Sep;84(18):9149-60. 5.150

 

Faaij CM, Annels NE, Ruigrok G, van der Burg M, Ball LM, Bredius RG, et al. Decrease of skin infiltrating and circulating CCR10+ T cells coincides with clinical improvement after topical tacrolimus in Omenn syndrome. J Invest Dermatol. 2010 Jan;130(1):308-11. 5.543

 

Faaij CM, Willemze AJ, Revesz T, Balzarolo M, Tensen CP, Hoogeboom M, et al. Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr Blood Cancer. 2010 Aug;55(2):344-8. 2.134

 

Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res. 2010 Jun 1;16(11):3067-77. 6.747

 

Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):91-8. 6.489

 

Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, et al. The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Mol Ther. 2010 Dec;18(12):2085-93. 6.239

 

Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets. 2010 Mar 1;10(2):242-67. 5.129

 

Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, et al. Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Mol Ther. 2010 Sep;18(9):1599-605. 6.239

 

Ismail M, Morgan R, Harrington K, Davies J, Pandha H. Immunoregulatory effects of freeze injured whole tumour cells on human dendritic cells using an in vitro cryotherapy model. Cryobiology. 2010 Dec;61(3):268-74. 1.718

 

James HE, Ebert K, McGonigle R, Reid SM, Boonham N, Tomlinson JA, et al. Detection of African swine fever virus by loop-mediated isothermal amplification. J Virol Methods. 2010 Mar;164(1-2):68-74. 2.133

 

John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, et al. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol. 2010;11:14. 2.724

 

Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H, et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest. 2010 May 3;120(5):1551-60. 15.387

 

Michael A, John J, Meyer B, Pandha H. Activation and genetic modification of human monocyte-derived dendritic cells using attenuated Salmonella typhimurium. ScientificWorldJournal. 2010;10:393-401. 2

 

Michael A, Relph K, Pandha H. Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents. Int J Cancer. 2010 Sep 1;127(6):1251-8. 4.722

 

Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer. 2010;10:89. 2.736

 

Pencavel T, Seth R, Hayes A, Melcher A, Pandha H, Vile R, et al. Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow? Gene Ther. 2010 Aug;17(8):949-60. 4.745

 

Price DL LS, Han Z, Simpson G, Coffin RS, Wong J, Li S, Fong Y, Wong RJ, . Oncolysis using Herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head an neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2010;136(2):151-8. 1.918

 

Wong J KK, Mittra A, Gonzalez SJ, Song KY, Simpson G, Coffin R, Fong Y. A third generation herpesvisus is effective against gastroesophageal cancer. J Surg Res. 2010;163(2):214-20. 2.176

 

2009

 

Agrawal VK, Copeland KM, Barbachano Y, Rahim A, Seth R, White CL, et al. Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery. Gene Ther. 2009 Jan;16(1):78-92. 4.745

 

da Costa CE, Szuhai K, van Eijk R, Hoogeboom M, Sciot R, Mertens F, et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer. 2009 Mar;48(3):239-49. 3.858

 

Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer. 2009 Sep 15;125(6):1372-9. 4.722

 

Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 2009 May;16(5):689-99. 4.745

 

Ismail M, Bokaee S, Morgan R, Davies J, Harrington KJ, Pandha H. Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy. Br J Cancer. 2009 Jun 16;100(12):1889-95. 4.346

 

Ismail M, Morgan R, Harrington K, Davies J, Pandha H. Enhancing prostate cancer cryotherapy using tumour necrosis factor related apoptosis-inducing ligand (TRAIL) sensitisation in an in vitro cryotherapy model. Cryobiology. 2009 Oct;59(2):207-13. 1.718

 

Pandha H, D'Ambrosio C, Heenan S, Hyde N, Di Palma S, Nutting C, et al. Indium-labelled autologous dendritic cells migrate to local lymph nodes after intratumoural injection in head and neck cancer patients. Clin Oncol (R Coll Radiol). 2009 May;21(4):363-4. 2.846

 

Pandha H, Melcher A, Harrington K, Vile R. Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009. Mol Ther. 2009 Jun;17(6):934-5. 6.239

 

Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res. 2009 Oct 1;15(19):6158-66. 6.747

 

Plowright L, Harrington KJ, Pandha HS, Morgan R. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer. 2009 Feb 10;100(3):470-5. 4.346

 

Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther. 2009 Oct;20(10):1119-32. 4.202

 

Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol. 2009 Oct 1;183(7):4312-21. 5.646

 

Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res. 2009 Jul 1;15(13):4374-81. 6.747

 

Prestwich RJ, Scott KJ, Brown J, Harnden P, Whelan P, Cartledge J, et al. The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. BJU Int. 2009 Mar;103(6):740-6. 2.865

 

Riley CL, Mathieu MG, Clark RE, McArdle SE, Rees RC. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? Cancer Immunol Immunother. 2009 Sep;58(9):1489-99. 3.791

 

2008

 

Alamara C, Karapanagiotou EM, Tourkantonis I, Xyla V, Maurer CC, Lykourinas M, et al. Renal oncocytoma: a case report and short review of the literature. Eur J Intern Med. 2008 Nov;19(7):e67-9. 1.385

 

Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54. 2.846

 

Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med. 2008 Jan;14(1):81-7. 27.136

 

Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol. 2008 May 1;180(9):6018-26. 5.646

 

Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther. 2008 Sep;15(18):1257-70. 4.745

 

Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther. 2008 Aug;10(4):362-70. 3.452

 

Havranek EG, Labarthe MC, Ward S, Anderson CJ, Whelan MA, Pandha H. A novel murine model of allogeneic vaccination against renal cancer. BJU Int. 2008 May;101(9):1165-9. 2.865

 

Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A, et al. Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res. 2008 Dec 1;68(23):9771-8. 7.543

 

Hingorani M, White CL, Zaidi S, Merron A, Peerlinck I, Gore ME, et al. Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res. 2008 Aug 1;14(15):4915-24.

6.747

Horvath A. And Mostafid H. Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. BJU International. 2008;103(6):726-9. 2.865

 

Ismail M, Pandha, H and Davies, J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: current status and future prospectives. Future medicine. 2008;5(1):37-45.

 

Li Y, Stirling CM, Denyer MS, Hamblin P, Hutchings G, Takamatsu HH, et al. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost. Vaccine. 2008 May 19;26(21):2647-56. 3.616

 

Lowenstein L, Kenton K, Dooley Y, E RM, Brubaker L. Women who experience detrusor overactive at lower bladder volumes report greater bother. Neurourol Urodyn. 2008;27(1):45-7. 4.984

 

Michael A, Syrigos K, Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis. 2009;12(1):13-6. 2.096

 

Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res. 2008 Feb 1;14(3):912-23. 6.747

 

Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008 Nov 1;14(21):7127-37. 6.747

 

White CL, Menghistu T, Twigger KR, Searle PF, Bhide SA, Vile RG, et al. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene Ther. 2008 Mar;15(6):424-33. 4.745

 

White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther. 2008 Jun;15(12):911-20. 4.745

 

Yap TA, Brunetto A, Pandha H, Harrington K, Debono JS. Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Investig Drugs. 2008 Dec;17(12):1925-35. 4.218

 

Morgan R and Whiting K. Differential expression of HOX genes upon activation of leukocytre sub-populations. Int J Haematol. 2008;87(256-249). 1.168

 

Papaetis GS, Karapanagiotou LM, Pandha H, Syrigos KN. Targeted therapy for advanced renal cell cancer: cytokines and beyond. Curr Pharm Des. 2008;14(22):2229-51. 4.414

 

Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res. 2008 Nov 15;14(22):7358-66. 6.747

 

Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8. 2.493

 

Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res. 2008 Jan 1;14(1):259-69. 6.747

 

Shears L, Plowright L, Harrington K, Pandha HS, Morgan R. Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J Urol. 2008 Nov;180(5):2196-201. 4.016

 

2007

 

da Costa CE, Egeler RM, Hoogeboom M, Szuhai K, Forsyth RG, Niesters M, et al. Differences in telomerase expression by the CD1a+ cells in Langerhans cell histiocytosis reflect the diverse clinical presentation of the disease. J Pathol. 2007 Jun;212(2):188-97. 6.466

 

Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, et al. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med. 2007 Feb;9(2):99-106. 2.968

 

Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007 Oct;100(4):760-4. 2.865

 

Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007 Jun;177(6):2136-40; discussion 40. 4.016